|
|
|
|
|
|
Sponsored by: |
NHS Greater Glasgow and Clyde |
Information provided by: | NHS Greater Glasgow and Clyde |
ClinicalTrials.gov Identifier: | NCT00335621 |
Some patients with chronic obstructive pulmonary disease (COPD) take nebulised treatments to ease the symptom of breathlessness, including the drug ipratropium. Nebulised bronchodilator drugs are taken up to 4 times through the day, and this can take up to 15 minutes each time. Although the treatment isbe effective, patients report that the time taken to set-up and use the nebuliser can be a disincentive to regular use. By contrast, an inhaler device is easy to use following appropriate instruction, and takes only a few seconds to administer. Inhaled tiotropium is a once daily treatment taken by inhaler which has been shown to be effective in COPD. We wish to assess whether inhaled Tiotropium as effective as nebulised ipratropium in patients with stable chronic obstructive pulmonary disease.
Condition | Intervention | Phase |
Chronic Obstructive Pulmonary Disease |
Drug: Inhaled Tiotropium |
Phase IV |
MedlinePlus related topics: | COPD (Chronic Obstructive Pulmonary Disease) |
ChemIDplus related topics: | Tiotropium Tiotropium bromide Ipratropium Ipratropium bromide |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Efficacy Study |
Official Title: | Replacement of Nebulised Ipratropium With Inhaled Tiotropium in Stable COPD |
Estimated Enrollment: | 45 |
Study Start Date: | June 2006 |
Estimated Study Completion Date: | December 2007 |
Show Detailed Description |
Ages Eligible for Study: | 35 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: George W Chalmers, MD | +44 141 211 4000 ext 4381 | George.Chalmers@northglasgow.scot.nhs.uk |
Contact: Anne Boyter, PhD | +44 141 548 4594 | anne.boyter@strath.ac.uk |
United Kingdom | |||||
Department of Respiratory Medicine, Glasgow Royal Infirmary | Not yet recruiting | ||||
Glasgow, United Kingdom, G4 0SF | |||||
Contact: George W Chalmers, MD +44 141 211 4000 ext 4381 George.Chalmers@northglasgow.scot.nhs.uk | |||||
Contact: Anne Boyter, PhD +44 141 548 4594 anne.boyter@strath.ac.uk | |||||
Principal Investigator: George W Chalmers, MD |
NHS Greater Glasgow and Clyde |
Principal Investigator: | George W Chalmers, MD | NHS Greater Glasgow and Clyde |
Principal Investigator: | Anne Boyter, PhD | Strathclyde University |
Study ID Numbers: | RN05RM001, REC 05/S0709/45, SSA 05/S0704/40 |
First Received: | June 8, 2006 |
Last Updated: | June 12, 2006 |
ClinicalTrials.gov Identifier: | NCT00335621 |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
|
|
|
|
|